Vuong Trieu Buys Shares of Oncotelic Therapeutics, Inc.
On June 24, 2026, CEO Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics.
Key Points
- On June 24, 2026, Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, bought 115,000 shares at $0.05 each.
- Shares of Oncotelic Therapeutics traded near $0.04 on Thursday, with a market cap of about $22.2 million.
- Recent insider buying includes multiple purchases by Trieu and CFO Amit Shah, reflecting ongoing interest in the company.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Vuong Trieu, the Chairman and CEO of Oncotelic Therapeutics, Inc. (OTC Markets OTCQB: OTLC), bought 115,000 shares of the company. The shares were purchased at an average price of $0.05, totaling about $5,750. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Oncotelic Therapeutics, Inc.
In addition to the recent purchase on June 24, Vuong Trieu has been actively buying shares throughout June. On June 23, he acquired 75,000 shares, and on June 22, he bought another 65,000 shares, both at $0.05 per share. Earlier, on June 17, Trieu purchased 239,759 shares at $0.04 per share. The company's CFO, Amit Shah, also bought 20,000 shares at $0.05 on June 22.
Oncotelic Therapeutics, Inc. Stock Up 33.3%
Shares of Oncotelic Therapeutics traded near $0.04 on Thursday. The company has a market capitalization of approximately $22.2 million. Its P/E ratio is notably low at 0.08, indicating a very low earnings multiple. The stock's 52-week range is between $0.02 and $0.11, with a 50-day moving average of $0.05 and a 200-day moving average of $0.07. The company's beta is -0.317, suggesting it might be less volatile than the market.
$OTLC stock price
Daily closing prices, year to date. Not investment advice.
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc. is a biopharmaceutical company based in Agoura Hills, California. The company focuses on developing treatments for rare cancer types. It works on antisense and small molecule injectable drugs for cancer treatment. Oncotelic is also developing drugs for acute myeloid leukemia, pancreatic cancer, and other conditions. Led by Dr. Vuong Trieu, the company employs 38 people and is involved in innovative drug development to address unmet medical needs.
Bottom Line
Vuong Trieu's recent share purchases highlight his confidence in Oncotelic Therapeutics' future. Investors often watch insider buying as a potential indicator of a company's prospects. However, it's important to remember that these transactions are disclosed after they occur and may not reflect the current state of the company's stock. As always, due diligence is crucial when considering any investment.
Get Oncotelic Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OTLC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.